Advertisement
Screener

OBSIDIAN THERAPEUTICS, INC. (OBX) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

2.8 / 5 stars · 68/120 Roast Me

OBSIDIAN THERAPEUTICS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

OBSIDIAN THERAPEUTICS, INC. (OBX) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of $25.86 million for the 3-month period ending 2026-06-30, per its S-1 filed 2026-08-28.

Financial Statements › Income Statement › Net Income

us-gaap:ProfitLoss · last filed 2026-08-28

  • OBSIDIAN THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was $25.86M, a 3.84% decline year-over-year.
  • OBSIDIAN THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was $26.90M.
Period endNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month
2026-06-30$25.86M
S-1 · filed 2026-08-28
$45.50M
S-1 · filed 2026-08-28
2025-12-31-$100.61M
S-1 · filed 2026-08-28
2025-06-30$26.90M
S-1 · filed 2026-08-28
$51.88M
S-1 · filed 2026-08-28
2024-12-31-$83.11M
S-1 · filed 2026-08-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74
GERON CORP (GERN)United States$0.803B-12.14
ARDELYX, INC. (ARDX)United States$0.857B-22.86
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
Olema Pharmaceuticals, Inc. (OLMA)United States$0.790B-5.35
Wave Life Sciences, Inc. (WVE)$0.780B-5.56
Cryoport, Inc. (CYRX)United States$0.881B-21.29